It is the second licensing deal involving siRNA between GSK and a Chinese biotech in the last few months, coming after the UK ...

Bayer has agreed terms for its first biopharma acquisition in years, paying $300 million upfront for privately-held US ...

The closed sites include some that came with its $1.25 billion takeover of CureVac last year, and BioNTech has said it hopes ...

While still making up a modest part of that total, oral Wegovy (semaglutide) performed better than expected since its launch ...

Navdeep "Navi" Chadha is co-founder and CTO of Axtria, a global provider of AI-powered data analytics and cloud software for ...

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL). The US regulator ...

The final ICH E6 (R3) Good Clinical Practice (GCP) Guidelines were published on 6 th January 2025, updating the framework for clinical trials to reflect modern trial designs, technology, and data ...

Novartis has signed its second licensing deal with Monte Rosa Therapeutics in less than a year, suggesting it is impressed with the US biotech's molecular glue degrader (MGD) platform. The latest ...

Bayer has its first regulatory approval for elinzanetant as a non-hormonal treatment for menopausal symptoms – in the UK – as it chases down a rival therapy from Astellas. The Medicines and Healthcare ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

After failing to muster sufficient support for an IPO last year, autoimmune and inflammatory disease specialist Odyssey ...

NHS England has awarded a new contract to US data analytics company Palantir to transition existing NHS projects into a new federated data platform (FDP), prompting pushback from organisations unhappy ...